Article info

Original research
Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx)

Authors

  1. Correspondence to Prof. Dr. Bart Neyns; bart.neyns{at}uzbrussel.be
View Full Text

Citation

Awada G, Ben Salama L, De Cremer J, et al
Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx)

Publication history

  • Accepted September 16, 2020
  • First published October 16, 2020.
Online issue publication 
October 16, 2020
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.